Literature DB >> 9549033

Use of botulinum toxin in the treatment of achalasia.

T D Schiano1, H P Parkman, L S Miller, M A Dabezies, S Cohen, R S Fisher.   

Abstract

Achalasia is a chronic esophageal motor disorder characterized by failure of the lower esophageal sphincter (LES) to relax during swallowing, aperistalsis of the esophageal body, and, often, an elevated resting LES pressure. Pneumatic dilation and Heller cardiomyotomy have been the time-honored, accepted treatments, but each may carry significant morbidity. Recently, intrasphincteric injection of botulinum toxin has been shown to be an effective treatment for achalasia, probably by reducing the excitatory cholinergic tone of the LES. Subjective and objective improvement have been reported in many patients with few reported adverse reactions. Clinical improvement generally lasts 2-6 months with patients often requiring repeat treatment. Although studies directly comparing botulinum toxin injection with pneumatic dilation and surgical myotomy are needed, botulinum toxin injection has rapidly become another therapeutic option in the treatment of achalasia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9549033     DOI: 10.1159/000016845

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  3 in total

Review 1.  Neuromyogenic properties of the internal anal sphincter: therapeutic rationale for anal fissures.

Authors:  R Bhardwaj; C J Vaizey; P B Boulos; C H Hoyle
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

Review 2.  Botulinum toxin in clinical practice.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

3.  Achalasia in a patient with gastroesophageal varices: problematic treatment decisions.

Authors:  Hugo Pinillos; Peter Legnani; Thomas Schiano
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.